Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma.
Level V
Where this comes from
- Record sourced from PubMed, PMID 29596546.
- Also identified by DOI 10.1001/jamaoncol.2018.0111.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Is rituximab maintenance therapy after first-line induction chemoimmunotherapy for follicular lymphoma associated with improved outcomes? Compared with observation, rituximab maintenance therapy prolongs progression-free survival without an improvement in overall survival or quality of life after first-line induction chemoimmunotherapy.
Medical subject headings
- Antineoplastic Agents
- Lymphoma, Follicular